Диссертация (1140686), страница 18
Текст из файла (страница 18)
98-102.17. Мирзаев К.Б., Сычев Д.А., Каркищенко В.Н., Грачев А.В., Князева Г.П.,Казаков Р.Е., Карасёв А.В. Частота полиморфных маркеров CYP2C19*2,CYP2C19*3,CYP2C19*17средирусскойпопуляцииисравнениераспространенности CYP2C19*2 у пациентов с ишемической болезнью сердца,получающих терапию клопидогрелем, и здоровых добровольцев // Биомедицина.– 2013. – №1. – с. 117-128.18. Новик, А.А. Руководство по исследованию качества жизни в медицине /А.А. Новик, Т.И. Ионова. – М.: ОЛМА Медиа Групп, 2007. – 320 с.19.
Оганесян, Т.С. Значение полиморфизма генов цитохрома-P4502C19 иинтерлейкина-1β для прогноза эффективности эрадикационной терапии язвеннойболезни желудка и двенадцатиперстной кишки, ассоциированной с Helicobacterpylori: автореф. дис. … канд. мед. наук : 14.00.05, 03.00.15 / Оганесян ТатьянаСергеевна. – М., 2008. – 24 с.20. Российский индекс научного цитирования, URL: http://www.elibrary.ru21. Сычев,Д.А.Фармакогенетическоетестирование:клиническаяинтерпретация результатов: рекомендации для практикующих врачей / Д.А.Сычев.
– М., 2011. – 88 с.22. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A,Manolopoulos VG. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6,CYP2C9, CYP2C19 and CYP3A5 in the Greek population // Clin. Pharmacol. – 2007. –21 (4). – p. 419-426.23. Babic Z,Svoboda-Beusan I, Kucisec-Tepes N, Dekaris D, TroskotR.Increased activity of Pgp multidrug transporter in patients with Helicobacter pyloriinfection // World J Gastroenterol. – 2005.
– 11. – p. 2720-2725.24. Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M,Eliasson E, Bertilsson L.Increased omeprazole metabolism in carriers of the121CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers // Br J ClinPharmacol. – 2008. – 65(5). – p. 767-74.25.
Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, WoosleyRL, Flockhart DA. The hydroxylation of omeprazole correlates with S-mephenytoinmetabolism: a population study // Clin Pharmacol Ther. – 1995. – 57(6). – p. 662-9.26. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamstercells in vitro: cross-resistance, radioautographic, and cytogenetic studies // Cancer Res.– 1970.
– 30(4). – p. 1174-84.27. Bozina N, Granić P, Lalić Z, Tramisak I, Lovrić M, Stavljenić-Rukavina A.Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 inCroatian population // Croat Med J. – 2003. – 44 (4). – p. 425-8.28. Brockmöller J, Rost KL, Gross D, Schenkel A, Roots I. Phenotyping ofCYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin andcomparison with the intron4/exon5 G-->A-splice site mutation // Pharmacogenetics. –1995.
– 5(2). – p. 80-8.29. Burget D. W., Chiverton K. D., Hunt R. H. Is there an optimal degree of acidsupression for healing of duodenal ulcers? A model of the relationship between ulcerhealing and acid suppression // Gastroenterology. – 1990. – 99. – p. 345-51.30. Chaudhry AS, Kochhar R, Kohli KK. Genetic polymorphism of CYP2C19 &therapeutic response to proton pump inhibitors // Indian J MedRes. – 2008.
– 127 (6). –p. 521-30.31. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB.Internal duplication and homology with bacterial transport proteins in the mdr1 (Pglycoprotein) gene from multidrug-resistant human cells // Cell. – 1986. – 47(3). – p.381-9.32. de Andrés F, Terán S, Bovera M, Fariñas H, Terán E, LLerena A.MultiplexPhenotyping for Systems Medicine: A One-Point Optimized Practical SamplingStrategy for Simultaneous Estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6Activities Using a Cocktail Approach // OMICS..
– 2016. – 20(2). – p. 88-96.12233. de Morais S.M. et al. Identification of a new genetic defect responsible for thepolymorphism of (S)-mephenytoin metabolism in Japanese // Mol Pharmacol. – 1994. –46(4). – p. 594-8.34. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA,Goldstein JA.
The major genetic defect responsible for the polymorphism of Smephenytoin metabolism in humans // J Biol Chem. – 1994. – 269(22). – p. 15419-22.35. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of thecytochrome P450 2C19 genetic polymorphism // Clin Pharmacokinet. – 2002. – 41(12).– p. 913-58.36. Dimenas E, Carlsson H, Glise H, Israelsson B, Wiklund I.Relevance of normvalues as part of the documentation of quality of life instruments for use in uppergastrointestinal disease // Scand J Gastroenterol.
– 1996. – 31 Suppl. – p. 8–13.37. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences inomeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer// Ann Intern Med. – 1998. – 129. – p. 1027-30.38. Furuta T, Shirai N, Kodaira M et al.Pharmacogenomics-based tailored versusstandard therapeutic regimen for eradication of H. pylori // Clin Pharmacol Ther. –2007. – 81(4). – p.
521-8.39. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics ofproton pump inhibitors // Pharmacogenomics. – 2004. – 5 (2). – p. 181-202.40. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K,Ishizaki T, Kaneko E. Effect of genotypic differences in CYP2C19 on cure rates forHelicobacter pylori infection by triple therapy with a proton pump inhibitor,amoxicillin, and clarithromycin // Clin.Pharmacol.Ther. – 2001. – 69 (3). – p. 158-68.41.
Furuta T, Sugimoto M, Shirai N, Matsushita F, Nakajima H, Kumagai J,Senoo K, Kodaira C, Nishino M, Yamade M, Ikuma M, Watanabe H, Umemura K,Ishizaki T, Hishida A. Effect of MDR1 C3435T polymorphism on cure rates ofHelicobacter pylori infection by triple therapy with lansoprazole, amoxicillin andclarithromycin in relation to CYP2C19 genotypes and 23S rRNA genotypes of H.pylori// Aliment Pharmacol Ther.
– 2007. – 26. – p. 693-703.12342. Furuta T, Sugimoto M, Shirai N. Individualized therapy for gastroesophagealreflux disease: potential impact of pharmacogenetic testing based on CYP2C19 // MolDiagn Ther. –2012. – 16 (4). – p. 223-34.43. Furuta T., Shirai N., Takashima M., Xiao F., Hanai H., Nakagawa K.,Sugimura H., Ohashi K., Ishizaki T.
Effects of genotypic differences in CYP2C19 statuson cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plusamoxicillin // Pharmacogenetics. – 2001. – 11 (4). – p. 341-8.44. Gaikovitch E.A., Cascorbi I., Mrozikiewicz P.M. et al. Polymorphisms ofdrug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of Pglycoprotein in a Russian population // Eur. J. Clin.
Pharmacol. – 2003. – 59. – p. 303312.45. Gardiner S. J., Begg E. J. Pharmacogenetics, Drug-Metabolizing Enzymes,and Clinical Practice // Pharmacol. Rev. – 2006. – 58. – p. 521-590.46. Gawrońska-Szklarz B, Siuda A, Kurzawski M, Bielicki D, Marlicz W,Droździk M. Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on theeradication rate of Helicobacter pylori infection by triple therapy with pantoprazole,amoxicillin, and metronidazole // Eur J Clin Pharmacol. – 2010. – 66(7).
– p. 681-7.47. Gawrońska-Szklarz B, Wrześniewska J, Starzyńska T, Pawlik A, Safranow K,Ferenc K, Droździk M. Effect of CYP2C19 and MDR1 polymorphisms on cure rate inpatients with acid-related disorders with Helicobacter pylori infection // Eur J ClinPharmacol. – 2005. – 61. – p. 375-379.48. Goddard AF, Jessa MJ, Barrett DA, Shaw PN, Idström JP, Cederberg C,Spiller RC.
Effect of omeprazole on the distribution of metronidazole, amoxicillin, andclarithromycin in human gastric juice // Gastroenterology. – 1996. – 111(2). – p. 35867.49. Google Академия, URL: http://www.scholar.google.ru50. Graham D.Y., Fischbach L. Helicobacter pylori treatment in the era ofincreasing antibiotic resistance // Gut. – 2010. – Vol. 59. – p. 1143—1153.12451. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC Jr.
Effect ofvarying pH on the susceptibility of Campylobacter pylori to antimicrobial agents // EurJ Clin Microbiol Infect Dis. – 1989. – 8(10). – p. 888-9.52. Gumus E., Karaca O., Babaoglu M.O. et al. Evaluation of lansoprazole as aprobe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlationin childhood // Eur J Clin Pharmacol. – 2012. – 68(5). – p. 629-36.53. Herman D., Dolzan V., Breskvar K.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
